Velarion · Company Intelligence
Compensation Brief
Fiscal year 2025 · Filings through 2026-09-03

Axsome Therapeutics (AXSM)

CEO Herriot Tabuteau was paid $10,283,492 in fiscal year 2025, ↓ down 0.8% from fiscal year 2024, the 57th percentile of its disclosed peer group (SEC filing 0001193125-26-177610 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.

$10,283,492 ↓
Herriot Tabuteau total, FY2025
57th
CEO pay percentile vs peers
23:1
CEO-to-median pay ratio
97.06%
Say-on-pay support, latest vote

Track this company's pay every filing: join the Pro seat waitlist

Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year

A confirmation now and one email when Pro opens, and nothing else. Privacy

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Herriot Tabuteau (Chief Executive Officer, President, and Chairman of the Board), FY2025 total compensation $10,283,492 (base salary $835,000) [exec_comp, SEC accession 0001193125-26-177610, filed 2026-04-24]

Answered within 24 hours, every figure cited to its SEC filing. If our database cannot answer your question, you are refunded automatically.

AXSM's next annual pay disclosure, estimated April 23, 2027.est. Filing ↗

01

Summary Compensation Table — fiscal year 2025

Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Herriot Tabuteau$835,000$0$5,533,554$2,833,237$876,750$0$204,951$10,283,492
Chief Executive Officer, President, and Chairman of the Board
Mark Jacobson575,00002,082,9431,066,620388,000095,5684,208,131
Chief Operating Officer
Nick Pizzie530,00001,822,596933,329358,000086,5943,730,519
Chief Financial Officer
Hunter Murdock530,00001,497,075766,593358,000072,6363,224,304
General Counsel
Ari Maizel530,00001,497,075766,593358,000036,9893,188,657
Chief Commercial Officer

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2025 totalFY2024 totalFY2023 totalΔ FY2024→2025
Herriot Tabuteau$10,283,492$10,364,688$9,896,629↓ −81,196
Mark Jacobson4,208,1314,245,8134,036,250↓ −37,682
Nick Pizzie3,730,5193,756,3893,565,817↓ −25,870
Hunter Murdock3,224,3043,245,5423,057,530↓ −21,238
Ari Maizel3,188,6573,198,5073,920,771↓ −9,850

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

You have just read Axsome Therapeutics's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper AXSM reports.

We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.

How we handle your data → Privacy

Companies that benchmark against AXSM
24 companies name AXSM as a compensation peer

The list of companies that name AXSM as a peer is temporarily unavailable — recheck shortly.

01c

Board of directors

One page per director: the seat, the committees and the fee table, read for one person at a time.

DirectorRoleFY2025 total
Mark ColemanLead Independent Director$514,745
Mark SaadIndependent Director$488,107
Roger JeffsIndependent Director$482,362
Susan MahonyIndependent Director$476,470
02

Equity transactions since the proxy statement was filed

Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Mark JacobsonChief Operating Officer2026-05-04D4,517$0$0Derivative, Class A CommonForm 4 ↗
Mark JacobsonChief Operating Officer2026-05-04D4,5172281,029,605Common, open-market saleForm 4 ↗
Mark JacobsonChief Operating Officer2026-05-04A4,5171358,495CommonForm 4 ↗
Dividend-equivalent accruals2026-05-05—233——1 insider, 1 accrual row
Mark JacobsonChief Operating Officer2026-05-05D23322853,166Common, open-market saleForm 4 ↗
Mark JacobsonChief Operating Officer2026-05-05A233133,017CommonForm 4 ↗
Mark ColemanDirector2026-05-29D6,0002331,400,760Common, open-market saleForm 4 ↗
Mark ColemanDirector2026-06-01D6,0002301,381,800Common, open-market saleForm 4 ↗
Mark ColemanDirector2026-06-02D5,5372231,236,910Common, open-market saleForm 4 ↗
Dividend-equivalent accruals2026-06-05—6,884——4 insiders, 4 accrual rows
Dividend-equivalent accruals2026-06-08—5,716——4 insiders, 4 accrual rows
Mark SaadDirector2026-06-08A1,429——CommonForm 4 ↗
Roger JeffsDirector2026-06-08A1,429——CommonForm 4 ↗
Mark ColemanDirector2026-06-08A1,429——CommonForm 4 ↗
Susan MahonyDirector2026-06-08A1,429——CommonForm 4 ↗
Herriot TabuteauDirector2026-06-09D49,67000Derivative, Class A CommonForm 4 ↗
Nick PizzieChief Financial Officer2026-06-09D33,00000Derivative, Class A CommonForm 4 ↗
Nick PizzieChief Financial Officer2026-06-09D33,0002407,922,970Common, open-market saleForm 4 ↗
Nick PizzieChief Financial Officer2026-06-09A33,0004115,500CommonForm 4 ↗
Susan MahonyDirector2026-06-09D30023771,163CommonForm 4 ↗
Herriot TabuteauDirector2026-06-09D49,67024111,970,967Common, open-market saleForm 4 ↗
Herriot TabuteauDirector2026-06-09A49,6705245,867CommonForm 4 ↗
Mark ColemanDirector2026-06-10D643249160,107Common, open-market saleForm 4 ↗
Susan MahonyDirector2026-06-10D30024673,854CommonForm 4 ↗
Roger JeffsDirector2026-06-10D28624670,407CommonForm 4 ↗
Roger JeffsDirector2026-06-11D28624971,248CommonForm 4 ↗
Herriot TabuteauDirector2026-07-01D49,66600Derivative, Class A CommonForm 4 ↗
Herriot TabuteauDirector2026-07-01D49,66624011,932,257Common, open-market saleForm 4 ↗
Herriot TabuteauDirector2026-07-01A49,6665245,847CommonForm 4 ↗
Herriot TabuteauDirector2026-08-05D45,00400Derivative, Class A CommonForm 4 ↗
Herriot TabuteauDirector2026-08-05D45,0042129,541,298Common, open-market saleForm 4 ↗
Herriot TabuteauDirector2026-08-05A45,0045222,770CommonForm 4 ↗
Herriot TabuteauDirector2026-08-06D4,66000Derivative, Class A CommonForm 4 ↗
Herriot TabuteauDirector2026-08-06D4,660214997,007Common, open-market saleForm 4 ↗
Herriot TabuteauDirector2026-08-06A4,660523,067CommonForm 4 ↗
Mark JacobsonChief Operating Officer2026-09-03D10,00000Derivative, Class A CommonForm 4 ↗
Mark JacobsonChief Operating Officer2026-09-03D10,0002092,086,500Common, open-market saleForm 4 ↗
Mark JacobsonChief Operating Officer2026-09-03A10,00013129,500CommonForm 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

View all 44 transactions
InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Mark JacobsonChief Operating Officer2026-05-04D4,517$0$0Derivative, Class A CommonForm 4 ↗
Mark JacobsonChief Operating Officer2026-05-04D4,5172281,029,605Common, open-market saleForm 4 ↗
Mark JacobsonChief Operating Officer2026-05-04A4,5171358,495CommonForm 4 ↗
Mark JacobsonChief Operating Officer2026-05-05D23300Derivative, Class A CommonForm 4 ↗
Mark JacobsonChief Operating Officer2026-05-05D23322853,166Common, open-market saleForm 4 ↗
Mark JacobsonChief Operating Officer2026-05-05A233133,017CommonForm 4 ↗
Mark ColemanDirector2026-05-29D6,0002331,400,760Common, open-market saleForm 4 ↗
Mark ColemanDirector2026-06-01D6,0002301,381,800Common, open-market saleForm 4 ↗
Mark ColemanDirector2026-06-02D5,5372231,236,910Common, open-market saleForm 4 ↗
Roger JeffsDirector2026-06-05A1,72100Derivative, Class A CommonForm 4 ↗
Mark SaadDirector2026-06-05A1,72100Derivative, Class A CommonForm 4 ↗
Mark ColemanDirector2026-06-05A1,72100Derivative, Class A CommonForm 4 ↗
Susan MahonyDirector2026-06-05A1,72100Derivative, Class A CommonForm 4 ↗
Mark ColemanDirector2026-06-08D1,42900Derivative, Class A CommonForm 4 ↗
Susan MahonyDirector2026-06-08D1,42900Derivative, Class A CommonForm 4 ↗
Mark SaadDirector2026-06-08D1,42900Derivative, Class A CommonForm 4 ↗
Mark SaadDirector2026-06-08A1,429——CommonForm 4 ↗
Roger JeffsDirector2026-06-08D1,42900Derivative, Class A CommonForm 4 ↗
Roger JeffsDirector2026-06-08A1,429——CommonForm 4 ↗
Mark ColemanDirector2026-06-08A1,429——CommonForm 4 ↗
Susan MahonyDirector2026-06-08A1,429——CommonForm 4 ↗
Herriot TabuteauDirector2026-06-09D49,67000Derivative, Class A CommonForm 4 ↗
Nick PizzieChief Financial Officer2026-06-09D33,00000Derivative, Class A CommonForm 4 ↗
Nick PizzieChief Financial Officer2026-06-09D33,0002407,922,970Common, open-market saleForm 4 ↗
Nick PizzieChief Financial Officer2026-06-09A33,0004115,500CommonForm 4 ↗
Susan MahonyDirector2026-06-09D30023771,163CommonForm 4 ↗
Herriot TabuteauDirector2026-06-09D49,67024111,970,967Common, open-market saleForm 4 ↗
Herriot TabuteauDirector2026-06-09A49,6705245,867CommonForm 4 ↗
Mark ColemanDirector2026-06-10D643249160,107Common, open-market saleForm 4 ↗
Susan MahonyDirector2026-06-10D30024673,854CommonForm 4 ↗
Roger JeffsDirector2026-06-10D28624670,407CommonForm 4 ↗
Roger JeffsDirector2026-06-11D28624971,248CommonForm 4 ↗
Herriot TabuteauDirector2026-07-01D49,66600Derivative, Class A CommonForm 4 ↗
Herriot TabuteauDirector2026-07-01D49,66624011,932,257Common, open-market saleForm 4 ↗
Herriot TabuteauDirector2026-07-01A49,6665245,847CommonForm 4 ↗
Herriot TabuteauDirector2026-08-05D45,00400Derivative, Class A CommonForm 4 ↗
Herriot TabuteauDirector2026-08-05D45,0042129,541,298Common, open-market saleForm 4 ↗
Herriot TabuteauDirector2026-08-05A45,0045222,770CommonForm 4 ↗
Herriot TabuteauDirector2026-08-06D4,66000Derivative, Class A CommonForm 4 ↗
Herriot TabuteauDirector2026-08-06D4,660214997,007Common, open-market saleForm 4 ↗
Herriot TabuteauDirector2026-08-06A4,660523,067CommonForm 4 ↗
Mark JacobsonChief Operating Officer2026-09-03D10,00000Derivative, Class A CommonForm 4 ↗
Mark JacobsonChief Operating Officer2026-09-03D10,0002092,086,500Common, open-market saleForm 4 ↗
Mark JacobsonChief Operating Officer2026-09-03A10,00013129,500CommonForm 4 ↗
03

Grants of plan-based awards — fiscal year 2025

ExecutiveAwardGrant dateThresholdTargetGrantedMaximumGrant-date fair value
Mark JacobsonOPTION2025-02-21——10,875—$1,066,620
Herriot TabuteauOPTION2025-02-21——28,887—2,833,237
Herriot TabuteauRSU2025-02-21——28,609—2,833,151
Mark JacobsonPSU2025-02-245,38510,769—21,5381,016,486
Herriot TabuteauPSU2025-02-2414,30528,609—57,2182,700,404
Nick PizzieOPTION2025-02-21——9,516—933,329
Nick PizziePSU2025-02-244,7129,423—18,846889,437
Ari MaizelPSU2025-02-243,8707,740—15,480730,579
Ari MaizelRSU2025-02-21——7,740—766,496
Nick PizzieRSU2025-02-21——9,423—933,159
Hunter MurdockRSU2025-02-21——7,740—766,496
Mark JacobsonRSU2025-02-21——10,769—1,066,457
Ari MaizelOPTION2025-02-21——7,816—766,593
03b

Vehicle mix — grant-date fair value by award type

Named executive officerTime-vested (RSU)Performance-vested (PSU)Options / SARs% performance-vested
Mark Jacobson$1,066,457$1,016,486$1,066,62032.3%
Herriot Tabuteau2,833,1512,700,4042,833,23732.3%
Nick Pizzie933,159889,437933,32932.3%
Ari Maizel766,496730,579766,59332.3%
Hunter Murdock766,496000.0%

% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.

04

Outstanding equity awards at fiscal year-end 2025

ExecutiveAwardShares unvestedExercise priceMarket value unvested
Nick PizzieOption16,15684—
Nick PizzieRSU13,379—2,443,541
Nick PizzieRSU265,000—48,399,596
Herriot TabuteauRSU35,540—6,491,026
Herriot TabuteauRSU31,200—5,698,368
Ari MaizelRSU9,616—1,756,266
Herriot TabuteauRSU28,609—5,225,148
Herriot TabuteauPSU28,609—5,225,148
Herriot TabuteauRSU27,715—5,061,868
Nick PizzieRSU11,997—2,191,132
Nick PizzieRSU11,745—2,145,107
Nick PizzieRSU10,294—1,880,096
Nick PizzieRSU11,707—2,138,166
Ari MaizelRSU10,868—1,984,932
Nick PizzieRSU10,769—1,966,850
Nick PizziePSU10,769—1,966,850
Nick PizzieRSU10,277—1,876,991
Nick PizzieOption8,835137.75—
Hunter MurdockRSU9,616—1,756,266
Nick PizzieRSU9,423—1,721,017
Nick PizziePSU9,423—1,721,017
Hunter MurdockRSU8,441—1,541,664
Hunter MurdockRSU7,740—1,413,634
Nick PizzieOption12,94565.32—
Hunter MurdockPSU7,740—1,413,634
Ari MaizelRSU7,740—1,413,634
Ari MaizelPSU7,740—1,413,634
Hunter MurdockRSU6,924—1,264,599
Nick PizzieOption11,32665.32—
Herriot TabuteauOption13,10329.91—
Herriot TabuteauOption34,38565.32—
Herriot TabuteauOption49,04584—
Nick PizzieOption5,58729.91—
Hunter MurdockOption6,350137.75—
Herriot TabuteauOption23,470137.75—
Nick PizzieOption4,86729.91—
Nick PizzieOption7,731137.75—
Nick PizzieOption18,46484—
Hunter MurdockOption3,27329.91—
Hunter MurdockOption9,30465.32—
Hunter MurdockOption13,27184—
Ari MaizelOption16,93570.73—
Ari MaizelOption13,27184—
Ari MaizelOption6,350137.75—
05

Incentive-plan design — the Compensation Discussion & Analysis

The company practices pay-for-performance, ensuring a significant percentage of NEO compensation is at-risk and tied to corporate and individual performance goals. They set challenging incentive plan goals for annual bonuses and PSUs, and align executive compensation with market practices by annually reviewing peer group companies.

CEO STI target (% of salary)70%
CEO LTI target (% of salary)—
Independent consultantFrederic W. Cook & Co., Inc.
Clawback policytrue
Anti-hedgingtrue
Anti-pledgingtrue
06

Say-on-pay — recent advisory votes

Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20262026-06-0537,818,384777,937366,15597.06%Passed
20252025-06-0634,776,343528,19953,60298.35%Passed
20242024-06-0732,850,943866,04667,34897.24%Passed
20232023-06-0226,607,318628,910524,33195.85%Passed
20222022-06-0320,675,256502,810164,38196.87%Passed
20212021-06-0423,304,240566,943480,22595.7%Passed

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.

Say-on-pay — history, company's computation

Meeting yearMeeting dateApproval — company's computation
20262026-06-0597.06%a
20252025-06-0698.35%b
20242024-06-0797.24%c

a. Approved under the standard stated in the filing — “Abstentions will have the effect of a vote against this proposal.”.

b. Approved under the standard stated in the filing — “Abstentions will have the effect of a vote against this proposal and broker non-votes will have no effect on the outcome of this proposal.”.

c. Approved under the standard stated in the filing — “Abstentions will have the effect of a vote against this proposal.”.

Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

07

CEO pay ratio

Ratio (CEO : median employee)23 : 1
CEO total compensation$10,283,492
Median employee compensation$437,980
08

Director compensation — fiscal year 2025

DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
Mark ColemanIndependent · Lead Independent Director · Compensation · Nominating and Corporate Governance · Audit$114,834$159,919$239,992$0$0$514,745
Mark SaadIndependent · Compensation · Nominating and Corporate Governance · Audit (Chair)88,196159,919239,99200488,107
Roger JeffsIndependent · Compensation · Nominating and Corporate Governance (Chair) · Audit82,451159,919239,99200482,362
Susan MahonyIndependent · Compensation (Chair) · Audit76,559159,919239,99200476,470
Herriot TabuteauEmployee director · Board Chair000—00
09

Board fee structure and ownership guideline

Annual cash retainer$50,000
Annual equity retainer$400,000
Per board meeting fee—
Committee chair fees (audit / comp / nom-gov)25,000 / 20,000 / 12,000
Stock ownership guideline—
09b

Total cost of the board

ComponentFY2025
Cash retainers and fees$362,040
Equity awards (grant-date value)$639,676
All other compensation$0
Total cost of the board$1,001,716

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

10

Disclosed peer group — fiscal year 2025

The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.

10a

Peer reciprocity

Of the companies Axsome Therapeutics names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.

Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Axsome Therapeutics.

10b

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1BridgeBio Pharma, Inc.2025Neil Kumar$1,044,000$10,606,275$1,874,992$0$14,944,585
2Apellis Pharmaceuticals, Inc.2024Cedric Francois793,1934,779,8324,787,768010,957,451
3Zai Lab Limited2025Samantha Du908,7303,233,7295,822,084695,17810,677,221
4Axsome Therapeutics2025Herriot Tabuteau835,0005,533,5542,833,237876,75010,283,492
5Revance Therapeutics, Inc2023Mark Foley720,0008,810,7310522,72010,068,915
6Allogene Therapeutics, Inc.2025David Chang724,0002,409,5372,588,329400,0106,136,093
7Alector, Inc.2025Arnon Rosenthal678,100422,876558,216325,4881,995,018
8Collegium Pharmaceutical, Inc.2025Vikram Karnani875,00000835,4061,715,846

Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

10c

Incentive design against the same peers

CompanyAnnual incentive payoutLong-term vehicle mixPSU measures include TSRCompensation consultant
Axsome Therapeutics150%RSU 33 · Options 33 · PSU 33NoFrederic W. Cook & Co., Inc.
Alector, Inc.80%not disclosednot disclosedPearl Meyer & Partners, LLC
Allogene Therapeutics, Inc.not disclosedOption 55 · RSU 25 · PSU 20not disclosedCompensia
Apellis Pharmaceuticals, Inc.90.74%RSU 50 · PSU 50not disclosedPay Governance
BridgeBio Pharma, Inc.135%RSU 50 · PSU 35 · Options 15NoAon Talent Solutions
Collegium Pharmaceutical, Inc.127.3%RSU 70 · PSU 30Yes — relative ranking of the total shareholder return (TSR) of the Company's common stock in 2025, 2026, 2027 and the cumulative three-year performance period (2025-2027) return relative to the TSR of peer companies within the S&P Pharmaceutical Select Industry IndexAlpine Rewards, LLC
Revance Therapeutics, Inc96.8%PSU 100NoFW Cook
Zai Lab Limited85%Options 65 · RSU 20 · PSU 15NoPearl Meyer

Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.

10d

Frequently asked questions

Who was the highest-paid executive at Axsome Therapeutics in fiscal 2025?
As disclosed, Herriot Tabuteau (Chief Executive Officer, President, and Chairman of the Board) was the highest-paid executive at Axsome Therapeutics in fiscal 2025, with total compensation of $10,283,492.
How does Axsome Therapeutics's chief executive pay compare to its disclosed peer group?
As disclosed, Herriot Tabuteau's total compensation ranked at the 57th percentile of Axsome Therapeutics's disclosed peer group.
What is Axsome Therapeutics's CEO-to-median employee pay ratio?
As disclosed, Axsome Therapeutics's CEO-to-median employee pay ratio was 23:1.
How did shareholders vote on Axsome Therapeutics's executive compensation?
As disclosed, 97.06% of shareholders supported Axsome Therapeutics's executive compensation in the latest say-on-pay vote.
How much does Axsome Therapeutics spend in total on board compensation for fiscal 2025?
As disclosed, Axsome Therapeutics reported total board compensation of $1,001,716 for fiscal 2025.

Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.

11

Source register

Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.

#SupportsDocumentFiledAccessionLocation in document
1Section 01, Herriot TabuteauDEF 14A2026-04-240001193125-26-177610Section “Summary Compensation Table” · page 32. As printed: 10,283,492. Filing ↗machine: t51 · r2 · c27 · span 900236–900246
2Section 01, Mark JacobsonDEF 14A2026-04-240001193125-26-177610Section “Summary Compensation Table” · page 32. As printed: 4,208,131. Filing ↗machine: t51 · r8 · c27 · span 961392–961401
3Section 01, Nick PizzieDEF 14A2026-04-240001193125-26-177610Section “Summary Compensation Table” · page 32. As printed: 3,730,519. Filing ↗machine: t51 · r5 · c27 · span 930748–930757
4Section 01, Hunter MurdockDEF 14A2026-04-240001193125-26-177610Section “Summary Compensation Table” · page 32. As printed: 3,224,304. Filing ↗machine: t51 · r11 · c27 · span 992037–992046
5Section 01, Ari MaizelDEF 14A2026-04-240001193125-26-177610Section “Summary Compensation Table” · page 32. As printed: 3,188,657. Filing ↗machine: t51 · r14 · c27 · span 1022662–1022671
6Section 03, Mark Jacobson OPTIONDEF 14A2026-04-240001193125-26-177610Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t50 · r6 · c5 · span 823568–823574
7Section 03, Herriot Tabuteau OPTIONDEF 14A2026-04-240001193125-26-177610Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t50 · r2 · c5 · span 796851–796857
8Section 03, Herriot Tabuteau RSUDEF 14A2026-04-240001193125-26-177610Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t50 · r2 · c9 · span 798226–798232
9Section 03, Mark Jacobson PSUDEF 14A2026-04-240001193125-26-177610Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t50 · r6 · c9 · span 824943–824949
10Section 03, Herriot Tabuteau PSUDEF 14A2026-04-240001193125-26-177610Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t50 · r2 · c9 · span 798226–798232
11Section 03, Nick Pizzie OPTIONDEF 14A2026-04-240001193125-26-177610Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t50 · r4 · c5 · span 810216–810221
12Section 03, Nick Pizzie PSUDEF 14A2026-04-240001193125-26-177610Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t50 · r4 · c9 · span 811590–811595
13Section 03, Ari Maizel PSUDEF 14A2026-04-240001193125-26-177610Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗
14Section 03, Ari Maizel RSUDEF 14A2026-04-240001193125-26-177610Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: span 1351467–1351474
15Section 03, Nick Pizzie RSUDEF 14A2026-04-240001193125-26-177610Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t50 · r4 · c9 · span 811590–811595
16Section 03, Hunter Murdock RSUDEF 14A2026-04-240001193125-26-177610Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t50 · r8 · c9 · span 838300–838305
17Section 03, Mark Jacobson RSUDEF 14A2026-04-240001193125-26-177610Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t50 · r6 · c9 · span 824943–824949
18Section 03, Ari Maizel OPTIONDEF 14A2026-04-240001193125-26-177610Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: span 1366840–1366847
19Section 07, pay ratioDEF 14A2026-04-240001193125-26-177610Section “CEO Pay Ratio”. As printed: 23 : 1. Filing ↗
20Section 08, Mark ColemanDEF 14A2026-04-240001193125-26-177610Section “Director Compensation”. As printed: 514,745. Filing ↗machine: span 578239–578447
21Section 08, Mark SaadDEF 14A2026-04-240001193125-26-177610Section “Director Compensation”. As printed: 488,107. Filing ↗machine: span 596590–596798
22Section 08, Roger JeffsDEF 14A2026-04-240001193125-26-177610Section “Director Compensation”. As printed: 482,362. Filing ↗machine: span 584356–584564
23Section 08, Susan MahonyDEF 14A2026-04-240001193125-26-177610Section “Director Compensation”. As printed: 476,470. Filing ↗machine: span 590482–590690
24Section 08, Herriot TabuteauDEF 14A2026-04-240001193125-26-177610Section “Director Compensation”. As printed: 0. Filing ↗
25Section 02, Mark Jacobson 2026-05-04Form 42026-05-050001193125-26-207148Insider equity transaction reported since the proxy statement. Filing ↗
26Section 02, Mark Jacobson 2026-05-04Form 42026-05-050001193125-26-207148Insider equity transaction reported since the proxy statement. Filing ↗
27Section 02, Mark Jacobson 2026-05-04Form 42026-05-050001193125-26-207148Insider equity transaction reported since the proxy statement. Filing ↗
28Section 02, Mark Jacobson 2026-05-05Form 42026-05-050001193125-26-207148Insider equity transaction reported since the proxy statement. Filing ↗
29Section 02, Mark Jacobson 2026-05-05Form 42026-05-050001193125-26-207148Insider equity transaction reported since the proxy statement. Filing ↗
30Section 02, Mark Jacobson 2026-05-05Form 42026-05-050001193125-26-207148Insider equity transaction reported since the proxy statement. Filing ↗
31Section 02, Mark Coleman 2026-05-29Form 42026-06-020001193125-26-254038Insider equity transaction reported since the proxy statement. Filing ↗
32Section 02, Mark Coleman 2026-06-01Form 42026-06-020001193125-26-254038Insider equity transaction reported since the proxy statement. Filing ↗
33Section 02, Mark Coleman 2026-06-02Form 42026-06-020001193125-26-254038Insider equity transaction reported since the proxy statement. Filing ↗
34Section 02, Roger Jeffs 2026-06-05Form 42026-06-090001193125-26-264030Insider equity transaction reported since the proxy statement. Filing ↗
35Section 02, Mark Saad 2026-06-05Form 42026-06-090001193125-26-264034Insider equity transaction reported since the proxy statement. Filing ↗
36Section 02, Mark Coleman 2026-06-05Form 42026-06-090001193125-26-264041Insider equity transaction reported since the proxy statement. Filing ↗
37Section 02, Susan Mahony 2026-06-05Form 42026-06-090001193125-26-264040Insider equity transaction reported since the proxy statement. Filing ↗
38Section 02, Mark Coleman 2026-06-08Form 42026-06-100001193125-26-266433Insider equity transaction reported since the proxy statement. Filing ↗
39Section 02, Susan Mahony 2026-06-08Form 42026-06-100001193125-26-266435Insider equity transaction reported since the proxy statement. Filing ↗
40Section 02, Mark Saad 2026-06-08Form 42026-06-100001193125-26-266436Insider equity transaction reported since the proxy statement. Filing ↗
41Section 02, Mark Saad 2026-06-08Form 42026-06-100001193125-26-266436Insider equity transaction reported since the proxy statement. Filing ↗
42Section 02, Roger Jeffs 2026-06-08Form 42026-06-100001193125-26-266437Insider equity transaction reported since the proxy statement. Filing ↗
43Section 02, Roger Jeffs 2026-06-08Form 42026-06-100001193125-26-266437Insider equity transaction reported since the proxy statement. Filing ↗
44Section 02, Mark Coleman 2026-06-08Form 42026-06-100001193125-26-266433Insider equity transaction reported since the proxy statement. Filing ↗
45Section 02, Susan Mahony 2026-06-08Form 42026-06-100001193125-26-266435Insider equity transaction reported since the proxy statement. Filing ↗
46Section 02, Herriot Tabuteau 2026-06-09Form 42026-06-090001193125-26-264038Insider equity transaction reported since the proxy statement. Filing ↗
47Section 02, Nick Pizzie 2026-06-09Form 42026-06-090001193125-26-264035Insider equity transaction reported since the proxy statement. Filing ↗
48Section 02, Nick Pizzie 2026-06-09Form 42026-06-090001193125-26-264035Insider equity transaction reported since the proxy statement. Filing ↗
49Section 02, Nick Pizzie 2026-06-09Form 42026-06-090001193125-26-264035Insider equity transaction reported since the proxy statement. Filing ↗
50Section 02, Susan Mahony 2026-06-09Form 42026-06-100001193125-26-266435Insider equity transaction reported since the proxy statement. Filing ↗
51Section 02, Herriot Tabuteau 2026-06-09Form 42026-06-090001193125-26-264038Insider equity transaction reported since the proxy statement. Filing ↗
52Section 02, Herriot Tabuteau 2026-06-09Form 42026-06-090001193125-26-264038Insider equity transaction reported since the proxy statement. Filing ↗
53Section 02, Mark Coleman 2026-06-10Form 42026-06-100001193125-26-266433Insider equity transaction reported since the proxy statement. Filing ↗
54Section 02, Susan Mahony 2026-06-10Form 42026-06-100001193125-26-266435Insider equity transaction reported since the proxy statement. Filing ↗
55Section 02, Roger Jeffs 2026-06-10Form 42026-06-110001193125-26-268202Insider equity transaction reported since the proxy statement. Filing ↗
56Section 02, Roger Jeffs 2026-06-11Form 42026-06-110001193125-26-268202Insider equity transaction reported since the proxy statement. Filing ↗
57Section 02, Herriot Tabuteau 2026-07-01Form 42026-07-010001193125-26-292985Insider equity transaction reported since the proxy statement. Filing ↗
58Section 02, Herriot Tabuteau 2026-07-01Form 42026-07-010001193125-26-292985Insider equity transaction reported since the proxy statement. Filing ↗
59Section 02, Herriot Tabuteau 2026-07-01Form 42026-07-010001193125-26-292985Insider equity transaction reported since the proxy statement. Filing ↗
60Section 02, Herriot Tabuteau 2026-08-05Form 42026-08-070001193125-26-340688Insider equity transaction reported since the proxy statement. Filing ↗
61Section 02, Herriot Tabuteau 2026-08-05Form 42026-08-070001193125-26-340688Insider equity transaction reported since the proxy statement. Filing ↗
62Section 02, Herriot Tabuteau 2026-08-05Form 42026-08-070001193125-26-340688Insider equity transaction reported since the proxy statement. Filing ↗
63Section 02, Herriot Tabuteau 2026-08-06Form 42026-08-070001193125-26-340688Insider equity transaction reported since the proxy statement. Filing ↗
64Section 02, Herriot Tabuteau 2026-08-06Form 42026-08-070001193125-26-340688Insider equity transaction reported since the proxy statement. Filing ↗
65Section 02, Herriot Tabuteau 2026-08-06Form 42026-08-070001193125-26-340688Insider equity transaction reported since the proxy statement. Filing ↗
66Section 02, Mark Jacobson 2026-09-03Form 42026-09-030001193125-26-382277Insider equity transaction reported since the proxy statement. Filing ↗
67Section 02, Mark Jacobson 2026-09-03Form 42026-09-030001193125-26-382277Insider equity transaction reported since the proxy statement. Filing ↗
68Section 02, Mark Jacobson 2026-09-03Form 42026-09-030001193125-26-382277Insider equity transaction reported since the proxy statement. Filing ↗
69Section 06, 2026 voteForm 8-K2026-06-090001193125-26-264043Item 5.07 · say-on-pay result. As reported: 97.06% (votes for as printed: 37,818,384). Filing ↗
70Section 06, 2025 voteForm 8-K2025-06-090000950170-25-083793Item 5.07 · say-on-pay result. As reported: 98.35% (votes for as printed: 34,776,343). Filing ↗
71Section 06, 2024 voteForm 8-K2024-06-110000950170-24-071960Item 5.07 · say-on-pay result. As reported: 97.24% (votes for as printed: 32,850,943). Filing ↗
72Section 01 trend, Δ column (computed)Computed——Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1)
73Section 03b vehicle mix (computed)Computed——RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio
74Section 09b board cost (computed)Computed——Cash 362,040 + equity 639,676 + all other 0 = 1,001,716, summed across the director compensation table rows.machine: formula: Σ = 1,001,716
75BridgeBio Pharma, Inc., Section 10b CEO totalDEF 14A2026-04-240001140361-26-016723CEO total compensation as printed in BridgeBio Pharma, Inc.'s own proxy. As printed: 14,944,585. Filing ↗machine: r2 · c21 · span 527521–527531
76Apellis Pharmaceuticals, Inc., Section 10b CEO totalDEF 14A2025-04-230000950170-25-056966CEO total compensation as printed in Apellis Pharmaceuticals, Inc.'s own proxy. As printed: 10,957,451. Filing ↗machine: r2 · c25 · span 951555–951565
77Zai Lab Limited, Section 10b CEO totalDEF 14A2026-04-280001704292-26-000030CEO total compensation as printed in Zai Lab Limited's own proxy. As printed: 10,677,221. Filing ↗machine: span 553414–553424
78Axsome Therapeutics (subject), Section 10b CEO totalDEF 14A2026-04-240001193125-26-177610CEO total compensation as printed in Axsome Therapeutics's own proxy. As printed: 10,283,492. Filing ↗machine: t51 · r2 · c27 · span 900236–900246
79Revance Therapeutics, Inc, Section 10b CEO totalDEF 14A2024-03-210001479290-24-000071CEO total compensation as printed in Revance Therapeutics, Inc's own proxy. As printed: 10,068,915. Filing ↗machine: span 884809–884819
80Allogene Therapeutics, Inc., Section 10b CEO totalDEF 14A2026-04-300001628280-26-028948CEO total compensation as printed in Allogene Therapeutics, Inc.'s own proxy. As printed: 6,136,093. Filing ↗machine: r2 · c54 · span 451014–451023
81Alector, Inc., Section 10b CEO totalDEF 14A2026-04-280001193125-26-186928CEO total compensation as printed in Alector, Inc.'s own proxy. As printed: 1,995,018. Filing ↗machine: span 1038665–1038674
82Collegium Pharmaceutical, Inc., Section 10b CEO totalDEF 14A2026-04-070001628280-26-024063CEO total compensation as printed in Collegium Pharmaceutical, Inc.'s own proxy. As printed: 1,715,846. Filing ↗machine: r2 · c48 · span 779394–779403
83Section 10a, Revance Therapeutics, Inc reciprocityDEF 14A—0001479290-24-000071Revance Therapeutics, Inc's most recent proxy was read; its disclosed peer group does not include Axsome Therapeutics. Filing ↗
84Section 10a, Apellis Pharmaceuticals, Inc. reciprocityDEF 14A—0000950170-25-056966Apellis Pharmaceuticals, Inc. names Axsome Therapeutics in its own disclosed peer group (read from its most recent proxy). Filing ↗
85Section 10a, Alector, Inc. reciprocityDEF 14A—0001193125-26-186928Alector, Inc.'s most recent proxy was read; its disclosed peer group does not include Axsome Therapeutics. Filing ↗
86Section 10a, Collegium Pharmaceutical, Inc. reciprocityDEF 14A—0001628280-26-024063Collegium Pharmaceutical, Inc.'s most recent proxy was read; its disclosed peer group does not include Axsome Therapeutics. Filing ↗
87Section 10a, Zai Lab Limited reciprocityDEF 14A—0001704292-26-000030Zai Lab Limited's most recent proxy was read; its disclosed peer group does not include Axsome Therapeutics. Filing ↗
88Section 10a, BridgeBio Pharma, Inc. reciprocityDEF 14A—0001140361-26-016723BridgeBio Pharma, Inc.'s most recent proxy was read; its disclosed peer group does not include Axsome Therapeutics. Filing ↗
89Section 10a, Allogene Therapeutics, Inc. reciprocityDEF 14A—0001628280-26-028948Allogene Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Axsome Therapeutics. Filing ↗

The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.

You'll confirm on The Pay Desk's sign-up page.